Ambika Ashraf
Pediatric Endocrinology · Birmingham, ALNPI 1134232226
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Chiesi USA, Inc. at 39.1% of the total. 2025 is the largest year on record at $15,955, more than ten times the $151 reported in 2019. Among pediatric endocrinology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $615.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$15K
- Sanofi$10K
- Biomarin Pharmaceutical Inc.$9K
- Regeneron$3K
- Novo Nordisk$249
- BETA Bionics, Inc.$226
- plus $1K from 14 others
Across 54 payments — averaging $2227.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$76K
- Amryt Pharma Holdings Ltd$43K
- Merck$2K
What the payments were for
- Consulting fees$12,47832%
- Speaking & faculty fees$20,21551%
- Travel & lodging$4,23411%
- Food & beverage$2,3356%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 6 | $15,419 |
| Sanofi | 5 | $10,273 |
| Biomarin Pharmaceutical Inc. | 21 | $9,198 |
| Regeneron | 2 | $2,860 |
| Novo Nordisk | 4 | $249 |
| BETA Bionics, Inc. | 3 | $226 |
| Sanofi-aventis U.S. LLC | 1 | $149 |
| Kyowa Kirin, Inc. | 1 | $126 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Tandem Diabetes Care, Inc. | 1 | $117 |
| Tolmar, Inc. | 1 | $114 |
| AstraZeneca | 1 | $100 |
| Abbott | 5 | $87 |
| Neurocrine Biosciences, Inc. | 1 | $73 |
| Amryt Pharma Holdings Ltd | 1 | $65 |
| Ultragenyx Pharmaceutical Inc. | 1 | $64 |
| Medtronic | 2 | $57 |
| Ferring Pharmaceuticals Inc. | 4 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JUXTAPID$15,044
- VOXZOGO 1.2mg$6,731
- EVKEEZA$2,860
- iLet Bionic Pancreas$428
- MYALEPT$300
- TZIELD$149
- CRYSVITA$126
- Tavalisse$125
- t:slim X2 Insulin Pump with Control-IQ$117
- FENSOLVI$114
How this compares
$39,401 in reported general payments places this provider in the 95th percentile of 22 pediatric endocrinology providers in Alabama.
Other pediatric endocrinology in Birmingham
- Mary ScottBirmingham$9K
- Kenneth McCormickBirmingham$2K
- Christy FosterBirmingham$1K
- Hussein Abdul-LatifBirmingham$728
- Giovanna BeauchampBirmingham$716
- Sajal PatelBirmingham$661
- Joycelyn AtchisonBirmingham$636
- Jessica SchmittBirmingham$607
- Mary BarrBirmingham$448
- Nicole BarnesBirmingham$309
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.